<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BASILIXIMAB </span><br/>(bas-i-lix'i-mab)<br/><span class="topboxtradename">Simulect<br/></span><b>Classifications:</b> <span class="classification"> immunosuppressant</span>; <span class="classification">monoclonal antibody</span>; <span class="classification">interleukin-2 receptor antibody</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Immunosuppressant agent that is an interleukin-2 receptor monoclonal antibody produced by recombinant DNA technology. Binds
         to and blocks interleukin-2R-alpha chain (CD-25 antibodies) on surface of activated T lymphocytes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binding to CD-25 antibodies inhibits a critical pathway in the immune response of the lymphocytes involved in allograft rejection.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis of acute renal transplant rejection.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity; serious infection or exposure to viral infections (e.g., chickenpox, herpes zoster); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of untoward reactions to dacliximab or other monoclonal antibodies; pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prophylaxis for Transplant Rejection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 20 mg times 2 doses (1st dose 2 h before surgery, 2nd dose 4 d after transplant)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>215 y</i>, 12 mg/m<sup>2</sup> (max: 20 mg/dose) times 2 doses (1st dose 2 h before surgery, 2nd dose 4 d after transplant)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV infusion:</span>  Add 5 mL sterile water for injection to a 20 mg vial, rock vial gently to dissolve then further dilute in an infusion bag
                  to a volume of 50 mL of NS or D5W. The resulting solution has a concentration of 2.5 mg/mL. Invert IV bag to dissolve but do not shake. Discard if diluted solution is colored or has particulate matter. Use IV solution immediately. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> Infuse the ordered dose of diluted drug over 2030 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>If necessary the diluted solution may be stored at room temperature for 4 h or at 2°8° C (36°46°
            F) for 24 h. Discard after 24 h.
         </li>
<li>Store undiluted drug at 2°8° C (36°46° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Pain, peripheral edema, edema, fever, viral infection, asthenia, arthralgia, acute hypersensitivity reactions with any dose. <span class="typehead">CNS:</span> Headache, tremor, dizziness, insomnia, paresthesias, agitation, depression. <span class="typehead">CV:</span> Hypertension, chest pain, hypotension, arrhythmias. <span class="typehead">GI:</span> Constipation, nausea, diarrhea, abdominal pain, vomiting, dyspepsia, moniliasis, flatulence, GI hemorrhage, melena, esophagitis,
      erosive stomatitis. <span class="typehead">Hematologic:</span> Anemia, thrombocytopenia, thrombosis, polycythemia. <span class="typehead">Respiratory:</span> Dyspnea, URI, cough, rhinitis, pharyngitis, bronchospasm. <span class="typehead">Skin:</span> Poor wound healing, acne. <span class="typehead">Urogenital:</span> Dysuria, UTI, albuminuria, hematuria, oliguria, frequency, renal tubular necrosis, urinary retention. <span class="typehead">Other:</span> Cataract, conjunctivitis. <span class="typehead">Metabolic:</span> Hyperkalemia, hypokalemia, hyperglycemia, hyperuricemia, hypophosphatemia, hypocalcemia, increased weight, hypercholesterolemia,
      acidosis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 36 days. <span class="typehead">Distribution:</span> Binds to interleukin-2R-alpha sites on lymphocytes. <span class="typehead">Half-Life:</span> 7.2 ± 3.2 d in adults, 11.5 ± 6.3 d in children. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for and immediately report S&amp;S of opportunistic infection or anaphylactoid reaction (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any distressing adverse effects.</li>
<li>Avoid vaccination for 2 wk following last dose of drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>